TL;DR
A working medical device prototype is an important milestone, but it does not automatically mean a product is ready for regulated manufacturing. The transition toward an ISO 13485 medical device contract manufacturer should usually begin when the program is approaching design verification, clinical builds, process development, packaging and sterilization validation, controlled manufacturing, or early commercialization. At this stage, the question is no longer simply whether the device works. The company needs to determine whether the product can be manufactured repeatedly, inspected consistently, documented appropriately, traced through production, and ultimately supported within a regulated quality system.
Bringing manufacturing expertise into the program before the design is completely frozen can help identify DFM issues, supplier risks, process variability, packaging challenges, documentation gaps, and manufacturing costs while the team still has options to address them. For medical device companies looking for a partner to help move a product from prototype toward manufacturing, Pathway MedTech supports this transition across medical device development, engineering, quality and regulatory support, design verification manufacturing, process development, ISO Class 7 cleanroom manufacturing, packaging, validation, sterilization coordination, and production-transfer readiness.
A Working Prototype Is a Milestone, Not Manufacturing Readiness
Reaching a functional prototype is one of the most important milestones in medical device development. It demonstrates that the underlying concept is technically feasible and gives engineers, clinicians, investors, and other stakeholders something tangible to evaluate. It is also where companies can become overly confident about how close the product is to manufacturing. A prototype is usually optimized around learning, which means engineers may rely on rapid machining, additive manufacturing, hand assembly, development-grade components, temporary fixtures, or highly skilled technicians to produce a relatively small number of units. Certain dimensions may still be adjusted manually, components may come from suppliers selected primarily for availability, and assembly instructions may still depend heavily on the people who developed the device.
None of this is unusual during early medical device prototyping. The issue arises when a company attempts to carry those prototype-oriented processes directly into design verification, clinical manufacturing, validation, or commercial production. At that point, the fundamental question changes from whether the device can be built to whether it can be defined, controlled, documented, inspected, and manufactured repeatedly. Medical device manufacturing requires design intent to be translated into controlled specifications, manufacturing processes, work instructions, inspection methods, supplier requirements, acceptance criteria, quality records, and traceable production documentation. Processes that depend heavily on individual operator knowledge may eventually require fixtures, tooling, defined parameters, training, process controls, or validation.
The closer a program moves toward regulatory submission and commercialization, the more these manufacturing decisions can affect cost, verification, validation, supply continuity, product quality, and launch timing. This is why manufacturing readiness should be treated as part of medical device development rather than something that begins only after engineering is finished. For companies searching for a medical device development and manufacturing partner, Pathway can become involved before the product reaches formal production transfer, allowing engineering, quality, regulatory, and manufacturing considerations to be evaluated together while there is still flexibility to improve the design and manufacturing approach.
When Should You Engage an ISO 13485 Contract Manufacturer?
One of the most common misconceptions in medical device development is that a contract manufacturer becomes relevant only when a device is ready for commercial production. In many programs, that is too late. The transition toward a regulated medical device manufacturing environment frequently begins much earlier, particularly when a company is preparing devices for design verification, clinical evaluation, process validation, packaging validation, sterilization activities, or controlled pilot production.
There is no universal prototype quantity or development milestone that automatically means a company must move to an ISO 13485 contract manufacturer. The right timing depends on the device, regulatory pathway, risk profile, manufacturing processes, intended use, development strategy, and commercialization plan. There is, however, a useful practical threshold: once the units being manufactured will generate important evidence, establish manufacturing processes, support regulatory activities, or materially influence the eventual commercial product, the way those devices are manufactured becomes increasingly important.
For example, a company preparing for design verification must be able to understand and control the configuration of the devices being tested. If verification units contain undocumented substitutions, inconsistent assembly methods, temporary components, or uncontrolled manufacturing variation, questions may arise regarding whether the test articles adequately represent the intended device. The objective is not to introduce unnecessary complexity into early development. It is to introduce the appropriate level of manufacturing control before critical program evidence begins depending on the product being built consistently.
This is an important distinction when evaluating medical device contract manufacturing companies. The right partner for a development-stage device may need to do considerably more than receive a finished design package and provide a unit price. The manufacturer may need to work alongside engineering and quality teams as the product moves through DFM, verification, process development, validation, and production readiness. Pathway supports pilot builds, design verification builds, validation lots, controlled manufacturing, cleanroom manufacturing, packaging and sterile barrier support, process validation support, and production-transfer readiness within its medical device manufacturing model.
Why ISO 13485 Matters as the Device Matures
ISO 13485 is sometimes discussed as though certification simply indicates that a medical device manufacturer operates a higher-quality facility. Its significance goes much deeper. ISO 13485 provides a quality management system framework specifically designed for organizations involved in the medical device lifecycle. The framework addresses documentation, risk management, purchasing controls, supplier management, production, traceability, validation, corrective action, and other systems required to consistently meet applicable medical device requirements.
This matters because medical device contract manufacturing is not simply the physical act of assembling components. The manufacturing system should create confidence that the approved device configuration can be produced under controlled conditions and that appropriate evidence exists to show what occurred during production. This became particularly relevant in the United States on February 2, 2026, when FDA’s Quality Management System Regulation, or QMSR, became effective. FDA’s revised 21 CFR Part 820 incorporates ISO 13485:2016 by reference as the foundation of the quality management system requirements for medical device manufacturers.
The practical implication for device developers is that quality and manufacturing considerations should not be treated as documentation exercises that begin immediately before commercialization. That does not mean every proof-of-concept prototype needs to be manufactured within an ISO 13485-certified organization. It does mean companies should recognize when development activities are beginning to feed into a product lifecycle that will ultimately depend on controlled specifications, supplier requirements, manufacturing processes, traceability, risk management, validation, and documented evidence.
Waiting until formal manufacturing transfer to introduce these considerations can create substantial remediation work. Drawings may need revision, supplier information may be incomplete, inspection requirements may not be adequately defined, manufacturing methods may be difficult to reproduce, and records may have been developed inconsistently or without sufficient configuration control. Pathway operates as an engineering-led medical device development and contract manufacturing partner, combining engineering, quality and regulatory support, manufacturing, and commercialization capabilities so that manufacturing readiness and quality requirements can be considered alongside product development rather than treated as isolated downstream activities.
Signal #1: Your Prototype Depends on the People Who Built It
One of the clearest signs that a medical device is ready for manufacturing development is when the product can be built successfully, but only by the engineer or technician who understands all of its nuances. During development, teams naturally accumulate undocumented knowledge. An engineer may know how much pressure to apply during an assembly step, how to orient a difficult component, which dimension tends to vary, or how to compensate for differences between supplier lots. An experienced technician may make small adjustments that are not formally documented but are necessary to create a functioning unit.
Those adjustments can be perfectly acceptable during prototyping, but they can also reveal future manufacturing risk. A repeatable medical device manufacturing process should not depend on individual craftsmanship or institutional memory where consistent execution is required. Critical knowledge eventually needs to be translated into drawings, specifications, tooling, fixtures, procedures, inspection criteria, process parameters, acceptance requirements, and training.
This is where medical device Design for Manufacturability, or DFM, becomes particularly valuable. DFM evaluates whether a product is not only technically functional but also practical to manufacture repeatedly and efficiently. A DFM review may identify unnecessarily tight tolerances, difficult assembly sequences, component interfaces that introduce variability, hard-to-inspect characteristics, fragile components, supplier limitations, or features that could become increasingly expensive as production grows.
Finding those issues before verification or significant tooling investment gives the development team more freedom to address them. Finding them after regulatory testing or design freeze can create a more difficult decision because the team may need to accept an inefficient process, invest in additional tooling or controls, or modify the device and determine what testing or documentation must be revisited. For companies looking for a medical device engineering and manufacturing company, this is one reason early manufacturing involvement can be valuable. Pathway’s development, engineering, and manufacturing capabilities allow DFM and manufacturing considerations to be evaluated before the device reaches final production transfer.
Signal #2: You Are Preparing for Design Verification
Design verification represents another important manufacturing inflection point. By this stage, the device should be progressing toward a controlled configuration. Verification is intended to demonstrate that design outputs satisfy established design inputs, which makes the configuration and manufacture of verification units increasingly important.
This does not mean every process needs to be optimized for large-scale manufacturing before verification. Many medical device companies appropriately conduct design verification using relatively small manufacturing runs. The important distinction is that the manufacturing approach should be deliberate, documented, and sufficiently controlled for the intended build. At this point, manufacturing engineers may begin defining assembly procedures, tooling, fixtures, manufacturing documentation, inspection points, material requirements, and other production controls. Quality functions can also help ensure that build records, traceability, deviations, nonconformances, configuration changes, and related documentation are appropriately managed.
Verification builds can also provide valuable manufacturing information. A bonding operation may prove highly sensitive to operator technique, a component may show unexpected supplier-to-supplier variability, an assembly may be more difficult to inspect than anticipated, or a critical dimension may be difficult to achieve consistently. These discoveries are not necessarily failures. When identified early enough, they provide the team with an opportunity to improve the design or manufacturing process before larger validation or commercial production activities occur.
For companies searching specifically for medical device verification manufacturing or an ISO 13485 manufacturer for design verification builds, Pathway supports regulated DV builds within its ISO 13485-certified environment, including DFM optimization, supplier qualification, controlled execution, and documentation intended to support regulatory submission and early commercialization.
Signal #3: Your Manufacturing Process Needs More Control
Another important threshold occurs when the manufacturing process itself begins becoming part of the quality and regulatory strategy. Some product characteristics can be fully verified through subsequent inspection or testing, while others cannot always be adequately confirmed after production without damaging the product, making testing impractical, or failing to fully demonstrate process performance. Depending on the device and manufacturing configuration, certain bonding, sealing, sterilization, welding, molding, coating, packaging, and other manufacturing processes may require additional process controls or validation.
Process validation should not be something a team attempts to develop immediately before commercial launch. First, the underlying manufacturing process needs to be understood. The team may need to determine which process variables influence product quality, establish appropriate operating ranges, develop fixtures or tooling, define inspection methods, train operators, establish manufacturing documentation, and understand how the process behaves across repeated builds. If the process is changing significantly every time the device is manufactured, it may not yet be mature enough for validation.
This is why manufacturing process development should precede formal process validation. At this stage, Pathway’s engineering and manufacturing teams can help translate prototype-oriented methods into more defined and repeatable manufacturing processes. Depending on the program, that can include process development, pilot builds, design verification builds, validation lots, manufacturing documentation, fixtures, tooling support, and process validation support. For a company evaluating medical device manufacturing services, the ability to work through this intermediate stage can be just as important as the ability to manufacture the finished commercial product.
Signal #4: Packaging and Sterilization Can No Longer Wait
Packaging is another area where prototype-oriented thinking can create significant downstream problems. During early development, packaging may primarily serve as a way to safely transport prototypes between engineers, laboratories, clinicians, or investors. For a finished medical device, particularly a terminally sterilized medical device, packaging becomes much more significant.
The packaging system may need to protect the device from physical damage, support the selected sterilization modality, maintain sterile barrier integrity, withstand expected distribution conditions, accommodate labeling requirements, and perform throughout the intended shelf life. These requirements can affect the device itself. Sharp features may interact poorly with sterile barrier materials, device geometry may complicate pouch or tray design, product materials may respond differently to EO, gamma, or electron beam sterilization, and package dimensions can affect shipping, storage, sterilization configuration, and manufacturing throughput.
If packaging development is postponed until the device is effectively finished, a seemingly simple packaging issue can create unexpected redesign or validation work. For medical device companies seeking medical device packaging validation, sterile barrier packaging, ISO 11607 packaging support, or cleanroom medical device packaging, integrating packaging with manufacturing can reduce the number of disconnected activities occurring late in development.
Pathway supports sterile barrier system development, pouch and tray sealing, packaging process validation, packaging integrity testing, accelerated and real-time aging, sterilization coordination, labeling support, cleanroom packaging, and production support. Connecting these activities with engineering and manufacturing allows packaging requirements to mature alongside the device rather than becoming a separate project immediately before commercialization.
Signal #5: Your Supply Chain Is Becoming Part of the Product
Prototype supply chains are usually optimized for speed. Production supply chains need to support considerably more. As a device moves toward regulated manufacturing, companies need greater confidence that components and materials can be sourced with appropriate specifications, documentation, consistency, lead times, quality, and commercial availability.
A component that performs perfectly in ten prototypes can still become a significant commercialization risk. The supplier may have minimum order quantities that create economic problems, lead times may not support future manufacturing schedules, material specifications may not be adequately controlled, a component may be at risk of discontinuation, incoming inspection requirements may not be clear, or a critical component may come from only one viable supplier. These issues can have implications beyond purchasing.
Changing a component or material later in the development process may require engineering evaluation, updated risk documentation, additional verification, supplier qualification, or regulatory assessment depending on the significance of the change. Supplier strategy therefore becomes part of medical device manufacturing readiness. The objective is not necessarily to establish a mature, high-volume supply chain during early prototyping. It is to identify which components and suppliers present meaningful technical, quality, or commercial risk before those risks affect verification, validation, or launch.
Pathway can support sourcing, supplier qualification, and vendor management as devices transition toward controlled manufacturing. Connecting these activities with engineering and manufacturing can help ensure that production planning reflects the materials, components, specifications, and suppliers intended to support the device moving forward. For organizations evaluating a medical device contract manufacturing partner, supply chain capability should therefore be considered alongside assembly and production capabilities.
Signal #6: You Need to Understand the Real Cost of Manufacturing
Prototype costs can be deceptive. A prototype may cost hundreds or thousands of dollars per unit because it uses rapid fabrication, engineering labor, one-off components, and very small purchasing quantities. Alternatively, a prototype may appear inexpensive because the company has not yet accounted for quality controls, incoming inspection, manufacturing documentation, validated processes, packaging, sterilization, supplier minimums, tooling, scrap, labor, and other requirements associated with controlled medical device manufacturing.
Neither number necessarily represents what the device will cost to manufacture. A more meaningful understanding of manufacturing cost becomes possible as the production process becomes clearer. Manufacturing involvement can expose where device architecture is driving labor, tooling requirements, component cost, inspection complexity, or potential yield challenges. Sometimes a relatively modest design change can simplify an assembly step or eliminate unnecessary manufacturing complexity. In other cases, a component that appears inexpensive on a bill of materials may introduce additional sourcing, handling, inspection, or assembly requirements that affect the overall manufacturing process.
These tradeoffs are easier to evaluate while engineering decisions remain flexible. Waiting until after design verification or regulatory submission can leave the team with fewer options for meaningful manufacturing improvements because design changes may require additional documentation, testing, or regulatory assessment. At Pathway, these considerations can be addressed through DFM, engineering collaboration, sourcing support, pilot manufacturing, and production-readiness planning while the device still has room to evolve.
For companies comparing medical device contract manufacturers, the lowest quoted unit cost during development is rarely the only consideration. Manufacturability, repeatability, quality requirements, supply continuity, validation needs, and the path toward future production all contribute to the real manufacturing picture.
Signal #7: You Are Approaching Controlled or Early Commercial Production
The transition into controlled and early commercial manufacturing creates a unique set of challenges. Production quantities may still be relatively modest, but the expectations surrounding product quality, documentation, traceability, and manufacturing control have changed substantially from early prototyping. Companies may need controlled assembly procedures, lot traceability, inspection documentation, manufacturing travelers, packaging and labeling controls, supplier controls, nonconformance procedures, environmental controls, and quality oversight. For some devices, cleanroom manufacturing may also become necessary.
At the same time, the manufacturing process may still be maturing. This creates a stage that can be difficult for development-stage medical device companies. A very large medical device contract manufacturer may be optimized around mature products, established transfer packages, significant volumes, and stable processes. A prototype shop may provide flexibility but may not offer the quality infrastructure required as a program progresses toward increasingly controlled builds. Companies at this stage often need something between those two models.
This transition from development into controlled manufacturing is a core part of Pathway’s model. Pathway supports pilot builds, design verification manufacturing, validation lots, process development, ISO Class 7 cleanroom manufacturing, packaging, quality documentation, and production-transfer readiness. Its public positioning focuses on supporting medical device companies from concept and prototype through validation, production, and commercialization.
For a company searching for low-volume medical device manufacturing, medical device pilot manufacturing, ISO 13485 cleanroom manufacturing, or an early-stage medical device contract manufacturer, this flexibility can be particularly important. It allows manufacturing processes to mature within a medical device quality environment without requiring the program to behave as though it has already reached mature high-volume production.
Do Not Wait Until the Design Transfer Meeting
A common approach is to complete product development internally and involve a contract manufacturer only when the formal medical device design transfer begins. For some mature products and experienced internal teams, that approach may work. For many development-stage medical device companies, however, it creates an unnecessary boundary between the people designing the product and the people who will eventually manufacture it.
The contract manufacturer receives drawings, specifications, the BOM, assembly procedures, test methods, and supplier information only after many of the fundamental engineering decisions have already been made. Manufacturing problems discovered at this stage can be expensive problems. A tolerance that was easy to specify may be difficult to manufacture consistently, an assembly sequence may create unnecessary labor, a selected supplier may not be suitable for regulated production, a component interface may produce inconsistent yields, or a packaging configuration may introduce challenges for sterilization or distribution.
Once verification is complete or the product configuration is substantially frozen, the team has fewer options. It may accept an inefficient process, invest in additional tooling or controls, or modify the device and evaluate the downstream verification and regulatory implications. Earlier manufacturing involvement creates another option: prevent the problem before the design is locked.
This is why medical device design transfer is better understood as a progression rather than a single meeting. Manufacturing knowledge should increasingly enter the development program as the device matures. Drawings, specifications, suppliers, inspection requirements, manufacturing processes, risk controls, tooling, and documentation can then develop together. For companies actively searching for medical device design transfer support, a partner capable of working before and during transfer can provide substantially more value than one whose involvement begins only when the transfer package is complete.
Pathway’s development and manufacturing model supports this progression from engineering into verification and controlled manufacturing, allowing teams to address DFM, sourcing, process development, quality documentation, and production readiness before formal manufacturing transfer becomes the bottleneck.
What Should You Look for in a Medical Device Contract Manufacturer?
ISO 13485 certification is an important starting point when evaluating a medical device contract manufacturer, but certification alone does not determine whether a manufacturer is appropriate for a particular program. The better question is whether the organization’s capabilities align with the current stage of the device and where it needs to go next.
A development-stage company may need a very different manufacturing partner than a mature medical device OEM transferring an established product into high-volume production. If a device is still approaching design verification, validation, or early manufacturing, the company may benefit from a partner capable of supporting DFM, engineering changes, supplier qualification, controlled verification builds, manufacturing process development, cleanroom assembly, packaging, validation, and production readiness. The manufacturer should also be able to work within the documentation and quality requirements associated with a regulated medical device program.
This is why a search for the best medical device contract manufacturer should go beyond equipment lists and per-unit pricing. Medical device companies should understand how prospective manufacturing partners approach traceability, manufacturing documentation, supplier controls, inspection, nonconformances, process changes, quality records, validation, and communication between engineering and manufacturing. Development-stage programs should also consider how easily manufacturing engineers can work directly with the product development team.
That is where Pathway’s structure can be particularly relevant. Pathway is not positioned solely as a production facility waiting to receive a completed manufacturing package. Its publicly described capabilities span medical device development, DFM, quality and regulatory support, design verification manufacturing, supplier qualification, ISO Class 7 cleanroom manufacturing, packaging and sterile barrier activities, process validation support, and production-transfer readiness. For development-stage medical device companies, that integration can reduce handoffs between separate organizations as the device progresses from engineering toward manufacturing and allows manufacturing issues to be addressed through design, process development, sourcing, documentation, or validation planning while the team still has flexibility to solve them.
The Best Transition Point Is Before Manufacturing Becomes the Bottleneck
There is no universal moment when every medical device company must leave prototyping behind. The transition is usually progressive. A team may continue using rapid prototypes for certain engineering activities while simultaneously beginning controlled manufacturing development for the configuration approaching verification. A company may manufacture relatively small quantities within an ISO 13485 environment long before it requires mature commercial-scale production.
What matters is recognizing when prototype-oriented processes are no longer sufficient for the next program objective. If the next units will support design verification, process validation, packaging validation, sterilization activities, regulatory evidence, pilot manufacturing, or early commercialization, manufacturing should already be part of the conversation. Likewise, if engineers are repeatedly solving the same assembly problems, supplier management is becoming increasingly difficult, documentation is struggling to keep pace with design changes, or the company cannot confidently explain how the product will be manufactured repeatedly, it may be time to bring medical device manufacturing expertise closer to the program.
The objective is not to introduce unnecessary bureaucracy. It is to avoid reaching a critical regulatory or commercialization milestone only to discover that the device works but the manufacturing system behind it is not ready.
Building the Path From Prototype to Production
The strongest medical device programs do not treat product development and manufacturing as completely separate activities. They allow the manufacturing strategy to mature alongside the device. Early prototypes answer questions about feasibility, engineering builds refine the design, DFM identifies potential production challenges, design verification builds establish increasingly controlled configurations, process development improves repeatability, and packaging and sterilization activities prepare the finished product for its intended lifecycle. Pilot and validation builds then generate additional knowledge about how the device will actually be manufactured.
For development-stage medtech companies, working with an ISO 13485 medical device contract manufacturer during this transition can also provide infrastructure that would otherwise need to be developed internally or coordinated across several separate vendors. Pathway MedTech is structured to support this transition across multiple disciplines rather than treating development and manufacturing as isolated activities. Pathway’s publicly described capabilities include medical device development, engineering, DFM, quality and regulatory support, design verification manufacturing, process development, ISO Class 7 cleanroom manufacturing, packaging and sterile barrier support, validation activities, sterilization coordination, supplier support, and production-transfer readiness.
This means Pathway can become involved before a device is completely finished and continue supporting the program as engineering decisions are translated into increasingly controlled manufacturing processes. For medical device companies asking who can manufacture my medical device, how to move a medical device prototype into production, or how to find an ISO 13485 contract manufacturer, the answer should begin with more than manufacturing capacity. The right partner should understand where the device is today, what the next regulatory and commercialization milestone requires, and what needs to happen between those two points.
The goal is not simply to manufacture the device that exists today. It is to establish the engineering, quality, documentation, supply chain, packaging, and manufacturing foundation required to move that device responsibly toward commercialization.
Building the Path From Prototype to Production
The strongest medical device programs do not treat product development and manufacturing as completely separate activities. They allow the manufacturing strategy to mature alongside the device. Early prototypes answer questions about feasibility, engineering builds refine the design, DFM identifies potential production challenges, design verification builds establish increasingly controlled configurations, process development improves repeatability, and packaging and sterilization activities prepare the finished product for its intended lifecycle. Pilot and validation builds then generate additional knowledge about how the device will actually be manufactured.
For development-stage medtech companies, working with an ISO 13485 medical device contract manufacturer during this transition can also provide infrastructure that would otherwise need to be developed internally or coordinated across several separate vendors. Pathway MedTech is structured to support this transition across multiple disciplines rather than treating development and manufacturing as isolated activities. Pathway’s publicly described capabilities include medical device development, engineering, DFM, quality and regulatory support, design verification manufacturing, process development, ISO Class 7 cleanroom manufacturing, packaging and sterile barrier support, validation activities, sterilization coordination, supplier support, and production-transfer readiness.
This means Pathway can become involved before a device is completely finished and continue supporting the program as engineering decisions are translated into increasingly controlled manufacturing processes. For medical device companies asking who can manufacture my medical device, how to move a medical device prototype into production, or how to find an ISO 13485 contract manufacturer, the answer should begin with more than manufacturing capacity. The right partner should understand where the device is today, what the next regulatory and commercialization milestone requires, and what needs to happen between those two points.
The goal is not simply to manufacture the device that exists today. It is to establish the engineering, quality, documentation, supply chain, packaging, and manufacturing foundation required to move that device responsibly toward commercialization.
- U.S. Food and Drug Administration: Quality Management System Regulation (QMSR)
FDA’s current overview of the Quality Management System Regulation, including incorporation of ISO 13485:2016 into 21 CFR Part 820 and the February 2, 2026 effective date. - U.S. Food and Drug Administration: QMSR Frequently Asked Questions
Additional FDA guidance addressing implementation of the revised medical device quality management system requirements. - ISO 13485:2016, Medical Devices Quality Management Systems
International quality management system standard specifically addressing organizations involved in the medical device lifecycle. - ISO 11607-1 and ISO 11607-2
International standards addressing packaging for terminally sterilized medical devices, including sterile barrier systems and validation requirements for forming, sealing, and assembly processes. - Pathway MedTech: Medical Device Manufacturing
Pathway’s overview of pilot builds, design verification manufacturing, validation lots, cleanroom manufacturing, packaging support, process validation support, traceability, and production-transfer readiness. - Pathway MedTech: Medical Device Verification Manufacturing
Information regarding Pathway’s support for regulated design verification builds, DFM optimization, supplier qualification, controlled execution, and documentation. - Pathway MedTech: Medical Device Packaging Services
Pathway’s sterile barrier system development, packaging validation, packaging testing, aging, sterilization coordination, labeling, cleanroom packaging, and production support.
